MGTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.94M

-81.58%

-0.570

+14%

1.81M

-6.22%

-0.580

+13.73%

1.81M

-51.06%

-0.578

+20.31%

Estimates Revision

The market is revising Downward the revenue expectations for MeiraGTx Holdings plc (MGTX) for FY2025, with the revenue forecasts being adjusted by -66% over the past three months. During the same period, the stock price has changed by -5.36%.

Revenue Estimates for FY2025

Revise Downward

-66%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+42.79%

In Past 3 Month

Stock Price

Go Down

-5.36%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is 23.00 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

15.00

Averages

23.00

High

30.00

Current: 0.000

Low

15.00

Averages

23.00

High

30.00

BofA

Buy

downgrade

$15 -> $14

2026-01-06

New

Reason

BofA

Price Target

$15 -> $14

2026-01-06

New

downgrade

Buy

Reason

BofA lowered the firm's price target on MeiraGTx to $14 from $15 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

H.C. Wainwright

Mitchell Kapoor

Buy

initiated

$20

2025-11-24

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

$20

2025-11-24

initiated

Buy

Reason

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx with a Buy rating and $20 price target. The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of the most "risk-mitigated late-stage gene therapy programs in development." It recommends buying the shares ahead of the pivotal data in late 2026 or early 2027.

Piper Sandler

Allison M. Bratzel

Overweight

maintain

$28 -> $30

2025-11-11

Reason

Piper Sandler

Allison M. Bratzel

Price Target

$28 -> $30

2025-11-11

maintain

Overweight

Reason

Piper Sandler analyst Allison M. Bratzel raised the firm's price target on MeiraGTx (MGTX) to $30 from $28 and keeps an Overweight rating on the shares following the news that the company has entered a broad strategic collaboration with Eli Lilly (LLY) to develop and commercialize genetic medicines in ophthalmology. This deal grants the latter worldwide exclusive rights to MeiraGTx's AAVAIPL1 program in LCA4. In exchange, MeiraGTx receives an upfront payment of $75M and is eligible to receive over $400M in total milestone payments and tiered royalties on licensed products. Piper thinks this is a positive development for MeiraGTx, which not only helps validate the company's technology, but provides non-dilutive capital through both upfront and milestone payments. The firm remains a buyer.

Raymond James

Strong Buy

initiated

$29

2025-10-20

Reason

Raymond James

Price Target

$29

2025-10-20

initiated

Strong Buy

Reason

Raymond James initiated coverage of MeiraGTx with a Strong Buy rating and $29 price target, citing the company's fully integrated manufacturing platform, unique vector constructs, and full ownership and "a major commercial interest in two legitimately large commercial opportunities addressing significant unmet needs." The firm derives a fair value of $29 per share just by modeling MeiraGTx's two lead programs - AAV-AQP1 for xerostomia and AAV-GAD for Parkinson's disease - but adds that "pipeline optionality abounds."

Lucid Capital

NULL -> Buy

initiated

$50

2025-06-09

Reason

Lucid Capital

Price Target

$50

2025-06-09

initiated

NULL -> Buy

Reason

Lucid Capital initiated coverage of MeiraGTx with a Buy rating and $50 price target. MeiraGTx is developing next-generation, genetic medicines to potentially unlock cures in chronic diseases, the analyst tells investors in a research note. The firm says the company is "providing a toolbox to pharma."

RBC Capital

Luca Issi

Buy

Maintains

$11 → $13

2025-03-17

Reason

RBC Capital

Luca Issi

Price Target

$11 → $13

2025-03-17

Maintains

Buy

Reason

RBC Capital raised the firm's price target on MeiraGTx to $13 from $11 and keeps an Outperform rating on the shares after its Q4 results. The company is very pleased with the terms of the deal announced with private AI company Hologen and notes that the process was competitive, the analyst tells investors in a research note. MeiraGTx is also planning to submit an MAA with UK regulators based on its LCA4 results with no need for additional studies, and is in discussions with FDA on a path forward, the firm adds.

Valuation Metrics

The current forward P/E ratio for MeiraGTx Holdings PLC (MGTX.O) is -4.39, compared to its 5-year average forward P/E of -11.44. For a more detailed relative valuation and DCF analysis to assess MeiraGTx Holdings PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.44

Current PE

-4.39

Overvalued PE

21.27

Undervalued PE

-44.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

4.15

Current EV/EBITDA

123.32

Overvalued EV/EBITDA

35.57

Undervalued EV/EBITDA

-27.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

26.23

Current PS

11.84

Overvalued PS

50.05

Undervalued PS

2.40

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 869.7% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MGTX News & Events

Events Timeline

No data

News

7.5

2025-11-10Benzinga

Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy

7.5

2025-11-10SeekingAlpha

Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders

4.0

2025-10-21Benzinga

Raymond James Begins Coverage of MeiraGTx Holdings with Strong Buy Rating and Sets Price Target at $29

People Also Watch

Frequently Asked Questions

What is MeiraGTx Holdings PLC (MGTX) stock price today?

The current price of MGTX is 7.41 USD — it has increased 1.79 % in the last trading day.

What is MeiraGTx Holdings PLC (MGTX)'s business?

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

What is the price predicton of MGTX Stock?

What is MeiraGTx Holdings PLC (MGTX)'s revenue for the last quarter?

MeiraGTx Holdings PLC revenue for the last quarter amounts to 410.00K USD, decreased -96.24 % YoY.

What is MeiraGTx Holdings PLC (MGTX)'s earnings per share (EPS) for the last quarter?

MeiraGTx Holdings PLC. EPS for the last quarter amounts to -0.62 USD, increased 12.73 % YoY.

What changes have occurred in the market's expectations for MeiraGTx Holdings PLC (MGTX)'s fundamentals?

How many employees does MeiraGTx Holdings PLC (MGTX). have?

MeiraGTx Holdings PLC (MGTX) has 381 emplpoyees as of January 11 2026.

What is MeiraGTx Holdings PLC (MGTX) market cap?

Today MGTX has the market capitalization of 596.44M USD.